Show simple item record

dc.contributor.authorQaseem, Amir
dc.contributor.authorYost, Jennifer
dc.contributor.authorEtxeandia-Ikobaltzeta, Itziar
dc.contributor.authorAbraham, George M.
dc.contributor.authorJokela, Janet A.
dc.contributor.authorForciea, Mary Ann
dc.contributor.authorMiller, Matthew C.
dc.contributor.authorHumphrey, Linda L.
dc.date2022-08-11T08:08:09.000
dc.date.accessioned2022-08-23T15:44:44Z
dc.date.available2022-08-23T15:44:44Z
dc.date.issued2021-02-09
dc.date.submitted2021-02-21
dc.identifier.citation<p>Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). Ann Intern Med. 2021 Feb 9. doi: 10.7326/M20-8101. Epub ahead of print. PMID: 33560862. <a href="https://doi.org/10.7326/M20-8101">Link to article on publisher's site</a></p>
dc.identifier.issn0003-4819 (Linking)
dc.identifier.doi10.7326/M20-8101
dc.identifier.pmid33560862
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27381
dc.description.abstractPractice points for clinicians developed by the American College of Physicians addressing these questions: What are the effectiveness and harms of remdesivir in hospitalized patients with coronavirus disease 2019 (COVID-19)? Do effectiveness and harms in hospitalized patients with COVID-19 vary by symptom duration, disease severity, and treatment duration?
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=33560862&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.7326/m20-8101
dc.subjectremdesivir
dc.subjecthospitalized patients
dc.subjectcoronavirus disease 2019
dc.subjectCOVID-19
dc.subjecteffectiveness
dc.subjectharms
dc.subjectHealth Services Administration
dc.subjectHealth Services Research
dc.subjectInfectious Disease
dc.subjectInternal Medicine
dc.subjectPatient Safety
dc.subjectTherapeutics
dc.subjectVirus Diseases
dc.titleShould Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)
dc.typeJournal Article
dc.source.journaltitleAnnals of internal medicine
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/178
dc.identifier.contextkey21761505
html.description.abstract<p>Practice points for clinicians developed by the American College of Physicians addressing these questions: What are the effectiveness and harms of remdesivir in hospitalized patients with coronavirus disease 2019 (COVID-19)? Do effectiveness and harms in hospitalized patients with COVID-19 vary by symptom duration, disease severity, and treatment duration?</p>
dc.identifier.submissionpathcovid19/178
dc.contributor.departmentDepartment of Medicine


This item appears in the following Collection(s)

Show simple item record